Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

被引：1
|
作者：
Rodon, J. [1 ]
Peltola, K. [2 ]
Azaro, A. [1 ]
Alvarez, E. Castanon [3 ]
Garratt, C. [4 ]
Leskinen, H. [5 ]
Bjorklund, H. [6 ]
Ruck, A. [4 ]
Massard, C. [3 ]
Bono, P. [2 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain
[2] Univ Helsinki, Cent Hosp, Comprehens Canc Ctr, Helsinki, Finland
[3] Inst Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[4] Orion Pharma, Oncol & Crit Care, Nottingham, England
[5] Orion Pharma, Drug Safety, Helsinki, Finland
[6] Orion Pharma, Drug Metab, Turku, Finland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
    Pant, Shubham
    Schuler, Martin
    Iyer, Gopa
    Witt, Olaf
    Doi, Toshihiko
    Qin, Shukui
    Tabernero, Josep
    Reardon, Davida A.
    Massard, Christophe
    Minchom, Anna
    Lugowska, Iwona
    Carranza, Omar
    Arnold, Dirk
    Gutierrez, Martin
    Winter, Helen
    Stuyckens, Kim
    Crow, Lauren
    Najmi, Saltanat
    Hammond, Constance
    Thomas, Shibu
    Santiago-Walker, Ademi
    Triantos, Spyros
    Sweiti, Hussein
    Loriot, Yohann
    LANCET ONCOLOGY, 2023, 24 (08): : 925 - 935
  • [42] Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
    Rosen, L. S.
    Wilding, G.
    Sweeney, C.
    Casale, D.
    Kollia, G.
    Wu, C.
    Ayers, M.
    Hill, C.
    Galbraith, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 133S - 133S
  • [43] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
    Hubbard, Joleen M.
    Yin, Jun
    Schenk, Erin L.
    Qin, Rui
    Reid, Joel M.
    Strand, Carrie
    Fiskum, Jack
    Menefee, Michael
    Lin, Grace
    Doyle, L. Austin
    Ivy, Percy
    Erlichman, Charles
    Adjei, Alex
    Haluska, Paul
    Costello, Brian A.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 115 - 123
  • [44] A phase study of OGT 719 in patients with advanced solid tumours
    Cassidy, J
    Carmichael, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S287 - S288
  • [45] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
    Joleen M. Hubbard
    Jun Yin
    Erin L. Schenk
    Rui Qin
    Joel M. Reid
    Carrie Strand
    Jack Fiskum
    Michael Menefee
    Grace Lin
    L. Austin Doyle
    Percy Ivy
    Charles Erlichman
    Alex Adjei
    Paul Haluska
    Brian A. Costello
    Investigational New Drugs, 2022, 40 : 115 - 123
  • [46] Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors
    Niwakawa, Masashi
    Yamaguchi, Raizo
    Onozawa, Yusuke
    Yasui, Hirofumi
    Taku, Keisei
    Naito, Tateaki
    Akinaga, Shiro
    Boku, Narikazu
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2013, 104 (08) : 1039 - 1044
  • [47] ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer
    Kamath, Suneel
    Tai, David
    Moreno, Irene
    Babiker, Hani
    Jin, Zhaohui
    Yoo, Changhoon
    Ricard, Fabien
    Jen, Kai Yu
    Coward, Jim
    Liu, Jia
    Opdam, Frans
    Millward, Michael
    Ponz-Sarvise, Mariano
    Yachnin, Jeffrey
    Kim, Richard
    Park, Joon Oh
    Subbiah, Vivek
    Schram, Alison M.
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Murakami, H.
    Yamamoto, N.
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Yamada, Y.
    Yamada, K.
    Puchalski, T.
    Shin, E.
    Tamura, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 124 - 124
  • [49] PHASE 1 STUDY OF THE SELECTIVE AKT INHIBITOR MK-2206 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Tanabe, Y.
    Doi, T.
    Tamura, K.
    Yonemori, K.
    Kodaira, M.
    Fuse, N.
    Bando, H.
    Maeda, Y.
    Shimamoto, T.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 164 - 164
  • [50] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
12345